Research Program: Women's Cancer

妇女癌症研究计划 由佩吉·波特博士和妮可·厄本博士领导的妇女癌症研究计划（WCRP）汇集了 一个高度跨学科的研究小组，致力于降低发病率和随后的死亡率 乳腺癌和妇科癌症的发病率该计划促进跨学科研究在FHCRC，华盛顿大学， 在临床社区，以改善癌症预防，检测，诊断和治疗。它有52个成员国 来自2个机构，4所学校和15个部门; 96%有同行评审的赠款资金或PI上 临床试验该计划拥有1120万美元的同行评审资金（直接美元），其中900万美元（80%）来自 NCI项目成员在过去5年中发表了583篇论文，其中16%是跨机构论文，19%是跨学科论文。 方案内手稿占35%，方案间手稿占16%，机构间手稿占16%。 该计划的中心研究主题包括改进识别高风险妇女的战略， 乳腺癌和妇科癌症，开发和验证用于乳腺癌早期诊断的检测方法， 妇科癌症，提高乳腺癌和妇科癌症过继性T细胞转移的有效性和安全性 癌症，并改善反应和降低对各种形式的化疗患者的耐药性， 乳腺癌和妇科癌症。 最近的科学成就包括阐明了病毒载量和变异体在宫颈癌中的作用， HPV感染的持续和进展;开发一种小的重组蛋白， 提高乳腺癌和卵巢癌单克隆和化疗药物疗效的潜力; 全面的基因检测，以确定妇女与遗传突变以外的那些确定为 BRCA 1/2; HE 4在上皮性卵巢癌筛查中的应用;避孕药的作用 醋酸甲羟孕酮、抗高血压和降脂药物有患乳腺癌的风险; 使用中枢记忆T细胞和嵌合抗原受体的过继性T细胞治疗的改进策略; 和定量FDG正电子发射断层扫描（PET）预测乳腺癌患者对芳香化酶抑制剂的反应 癌 许多研究、指导、项目开发以及项目间和项目内的互动都是 以三个大型多学科赠款为中心：太平洋卵巢癌研究联盟SPORE， 西雅图癌症联盟乳腺孢子，和NCI EDRN临床验证中心。此外该 该计划有一个广泛的优秀跨学科项目组合，包括成像， 免疫疗法和遗传学。项目领导层继续保持积极的研讨会议程， 资金和生物标本资源，以促进妇女癌症组织之间的方案目标和合作 成员和其他计划的成员。

Women's Cancer Research Program The Women's Cancer Research Program (WCRP), led by Drs. Peggy Porter and Nicole Urban, brings together a highly cross-disciplinary group of investigators dedicated to reducing the incidence and subsequent mortality of breast and gynecologic cancers. The program fosters interdisciplinary research at the FHCRC, the UW, and in the clinical community to improve cancer prevention, detection, diagnosis, and treatment. It has 52 members from 2 institutions, 4 schools and 15 departments; 96% have peer-reviewed grant funding or are PI on a clinical trial. The program holds $11.2M in peer reviewed funding (direct dollars), of which $9.0M (80%) is from NCI. Program members have published 583 papers in the last 5 years, including 16% inter-institutional, 19% intra-programmatic, 35% inter-programmatic and 16% inter-institutional manuscripts. Central research themes of the program include improving strategies for identifying women at high risk for breast and gynecological cancer, developing and validating assays for early diagnosis of breast and gynecological cancer, improving the efficacy and safety of adoptive T-cell transfer for breast and gynecological cancer, and improving response and lowering resistance to various forms of chemotherapy for patients with breast and gynecological cancer. Recent scientific accomplishments include elucidation of the role in cervical cancer of viral load and variants in the persistence and progression of HPV infections; development of a small recombinant protein that has the potential to enhance the efficacy of monoclonal and chemotherapeutic agents in breast and ovarian cancer; comprehensive genetic testing to identify women with inherited mutations beyond those determined as BRCA1/2; use of HE4 in screening for epithelial ovarian cancer; role of contraceptive depo- medroxyprogesterone acetate, antihypertensives and lipid lowering medications in risk of breast cancer; improved strategies for adoptive T-cell therapy using central memory T-cells and chimeric antigen receptors; and quantitative FDG positron emission tomography (PET) to predict response to aromatase inhibitor in breast cancer. Many of the research, mentoring, project development and inter-and intra-programmatic interactions are centered on three large multidisciplinary grants: the Pacific Ovarian Cancer Research Consortium SPORE, Seattle Cancer Consortium Breast SPORE, and the NCI EDRN Clinical Validation Center. In addition, the program has a broad portfolio of outstanding interdisciplinary projects including those in imaging, immunotherapy and genetics. Program leadership continues to maintain an active agenda of seminars, pilot funding and biospecimen resources to promote programmatic aims and collaboration among Women's Cancer members and with members of other programs.